Precision Biotherapeutics Remedies that Understand You

India’s biomanufacturing potential extends into healthcare through precision biotherapeutics, including cell and gene therapies, mRNA therapeutics, and monoclonal antibodies. The market for these therapies is expected to exceed $22 billion by 2027, and India is positioning itself as a global leader in this field. The BioE3 policy emphasizes building GMP-grade facilities for the development and production of precision biotherapeutics at scale, ensuring affordability and accessibility.

These innovations are crucial for addressing personalized medicine needs, targeting specific diseases with high precision, and enhancing the effectiveness of treatments. India’s expertise in biologics manufacturing will further support the development of cutting-edge therapies for both domestic and international markets.